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CCL3L1ion between a polymorphism and a disease phenotype through case-control
studies requires reliable large-scale genotyping, but accurate measurement of copy number variation has
proven to be technically challenging. Here we build on our previous experience with Paralogue Ratio Tests
(PRT) to develop PRT copy number determination at the CCL3L1/CCL4L1 copy number variant. A multiplex
PRT assay based on four independent comparative PCRs results in a convenient, accurate and robust method
of multiallelic copy number measurement suitable for use in large-scale case-control studies, which can
unambiguously assign virtually all samples tested to discrete copy number classes.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn recent years, it has emerged that copy number variation
contributes signiﬁcantly to the landscape of polymorphism in the
human genome [1]. However, accurate measurement of copy number,
particularly at multiallelic loci, presents an incompletely solved
technical challenge [2,3]. This is especially evident in large scale
case-control studies where the effects of experimental inaccuracy or
differential bias may disguise weak associations or (more danger-
ously) result in spurious positive results [4]. Armour et al. [5]
described a new method for the accurate measurement of copy
number, the Paralogue Ratio Test (PRT), which is in principle
applicable to many copy-variable loci. Brieﬂy, they used a single
primer pair to amplify precisely two products, one from a copy
variable region of interest and the other from a single copy reference
locus. Copy number of the test region was then estimated from the
ratio of test to reference products. Although PRT has been successfully
employed in a case-control study to identify an association between
DEFB4 copy number and psoriasis [6], used alone it did not produce
satisfactorily accurate data, with many samples not allocated
unambiguously to copy number classes. Here we describe the further
development of PRT in a multiplex adaptation, such that copy number
values fall into discrete clusters, and present an assay for the copy-
variable CCL3L1 region suitable for use in high throughput, large scale
case control studies.
Results
The CCL3L1 locus at 17q12 is amultiallelic copy variable region that
poses an interesting challenge for the development of methods for
typing multiallelic CNVs, with individuals generally possessingL. Armour).
l rights reserved.between 0 and 4 copies in Europe and up to 14 copies in Africa [7].
Copy number variation at CCL3L1 has recently been reported to be
associated with phenotypes such as HIV susceptibility [7], SLE [8] and
Rheumatoid Arthritis [9], highlighting the requirement for an accurate
copy number measurement assay for this region. The copy-variable
repeat unit is approximately 90 kb in length and encompasses two
genes, CCL3L1 and CCL4L1 [10,11]. It arose by duplication and
subsequent divergence from a neighbouring region spanning their
paralogues, CCL3 and CCL4.
We have designed three PRT systems which can be used in
combination to measure copy number at this locus, of which a
schematic diagram is shown in Fig. 1a. Two of the systems, “CCL3A”
and “CCL4A”, exploit indel differences between paralogues to test the
copy variable genes, CCL3L1 and CCL4L1, using their respective
paralogues, CCL3 and CCL4, as reference loci. The third system,
LTR61A, measures a Long Terminal Repeat situated between the two
genes against an unlinked reference locus on chromosome 10. There
are approximately 30 copies of LTR61 in the genome, but wewere able
to design primers to amplify exclusively from our test and reference
loci, with multiple mismatches to copies at other locations. Although
only CCL3A measures the copy number of CCL3L1 directly, the
additional systems provide a number of advantages. CCL4A is
empirically the most accurate of the three systems, and using the
unlinked reference locus LTR61A would allow any variation in the
copy number of CCL3 and CCL4 to be indirectly detected. Furthermore,
by having three systems at intervals along the repeat unit, the
integrity of the repeat can also be assessed.
For each sample, two duplex PCRs are carried out and mixed in a
single capillary for electrophoresis. This allows four separate ratios of
test to reference loci to be calculated, with two independent
measurements of LTR61A. Since in many laboratories the electrophor-
esis step contributes most to the cost of the test per sample,
combining the PCR products in a single capillary allows multiple
measures to enhance the accuracy of the test without proportionate
Fig. 1. (a) Schematic diagram showing the arrangement of the three PRT systems at the CCL3L1 locus. The “CCL3A” ratio measurement (green) compares the amount of PCR product
from CCL3L1 with the material ampliﬁed from CCL3, assumed to be present at single copy per haploid genome. Similarly, the “CCL4A” system (blue) measures the ratio of products
from CCL4L1with those from CCL4. “LTR61A” (red) compares product from the copy of this LTR in the CNV (above) against material ampliﬁed from an unlinked copy on chromosome
10, present at single copy. The multi-copy TBC1D3 gene ﬂanks the repeat unit, but is present at other locations on chromosome 17 and is not measured in this assay. (b) Typical
electrophoresis traces demonstrating multiplex PRT results from individuals with 0, 1, 2, 3 and 4 copies of CCL3L1 / CCL4L1.
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copies are shown in Fig. 1b. In the data presented here, in all but one
sample of poor DNA quality, there was unanimous agreement
between the different measurements on integer copy number, or a
single discrepant value within 0.75 of the consensus integer, and we
calculated copy number simply based on the average of the four
recorded values. If in other studies the level of disagreement between
measurements exceeds this threshold, then criteria for precise
judgments can be designed based on the required balance between
accuracy and throughput. In large-scale studies, composite likelihoodframeworks could be employed to deﬁne copy number calls according
to user deﬁned conditions.
We tested this combined system with 382 samples of European
origin, for which Fig. 2 shows the distributions of copy number
measurement values for the 369 of these individuals who were
unrelated. The observations clearly fall into clusters, and as expected
the combined results from multiplex PRT (Fig. 2e) improve the
accuracy compared with single PRT testing [5] to such an extent that
nearly all samples can be simply partitioned into discrete copy
number categories. The excellent general agreement between the
Fig. 2. Distribution of copy number values for 369 unrelated European samples. The
values from each of the four independent PRT assays (CCL3A, CCL4A and two
independent assays of LTR61A) are shown in panels (a) to (d), and comparison with
panel (e) shows the enhanced precision achievable by combining the individual results
into a mean copy number score.
Fig. 3. (a–c) Concordance of copy number measures in 382 European samples for (a)
CCL3A with CCL4A (b) CCL3A with LTR61A and (c) CCL4A with LTR61A.
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integer-discordant value within 0.75 of the consensus, we observed
only one example of discrepancy in copy number (see Materials and
methods). This implies that differences in an individual's copy number
for CCL3L1 and for CCL4L1, as proposed by Townson and others [11–
13], are rare in Europeans. Additionally, agreement with LTR61A
indicates that CCL3 and CCL4 do not commonly vary from 2 copies per
diploid genome.Inferred copy number values clustered around integer values, with
an overall standard deviation of 0.065 per copy. With this overall level
of accuracy, we predict the rate of incorrect integer calls for this
multiplex system in European samples to be less than 0.1%. Raw ratios,
calibrated values and inferred integer copy numbers for each sample
are listed in Supplementary Data online.
We designed two further assays to conﬁrm the accuracy of the
copy numbers reported by multiplex PRT. We identiﬁed two
microsatellites within the copy-variable repeat unit which are each
sufﬁciently variable to be informative in approximately 50% of
samples with two or more copies. Following PCR ampliﬁcation and
capillary electrophoresis, calculation of the relative dosage of different
sized products allowed the simple deﬁnition of the integer copy
number that best matches the allele ratios. Compared with PRT, these
systems are limited in their informativeness; two alleles of equal
representation are consistent with copy numbers of two, four or any
even number. However, these microsatellites do provide additional
support for the accuracy of the copy number as calculated by PRT,
particularly in samples of higher copy number where error is
predicted to be greater. Example traces from samples with 3 and 4
copies are shown in Figs. 4a and b. They have also enabled us to
Fig. 4. (a and b) Example microsatellite traces from individuals with 3 (Fig. 4a) and 4 (Fig. 4b) copies of CCL3L1/CCL4L1, with unrounded ratios between products shown in brackets.
Analysis of TATC17 peaks can be successfully carried out using the ratio of peak areas to calculate the relative amounts of product. However, a considerable amount of material in the
TTAT17 peaks resides in the visible ‘tail’ of the peaks which, in cases where products differ by less than 5 bases in size, prevents accurate quantiﬁcation of the amount of product due
tomis-assignment of material from the bigger product to the smaller. For this reason, peak heights were used in assessing the yield of alleles at TTAT17 rather than peak areas. There is
also appreciable size dependence in the yield of TTAT17 products and for improved accuracy the numbers shown include a correction for this effect.
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102 S. Walker et al. / Genomics 93 (2009) 98–103conﬁrm the copy number range of the locus as being commonly
between 0–4 copies in European samples. Further conﬁrmation of this
as the correct copy number range comes both from the relationship
between clusters of the raw PRT ratios (the means of which are
themselves in the ratios 1:2:3:4) and from analysis of the segregation
pattern of both linked markers and copy number in CEPH family 1408
[data not shown].
Discussion
To date, copy number measurement of CCL3L1 has mostly been
attempted by real-time PCR [7–9,11–13]. It remains to be demon-
strated in practice whether the accuracy we have achieved for
multiplex PRT in a few hundred measurements will be maintained
on scaling up to the analysis of thousands of samples, as currently
required in adequately-powered case–control association studies. We
are nevertheless not aware of any published data from real-time PCR
measurements of the CCL3L1/CCL4L1 variation that approach the
accuracy and resolution of this multiplex PRT assay (Figs. 2 and 3). The
real-time PCR assay may not only in itself be insufﬁciently accurate to
differentiate reliably between CCL3L1 copy numbers in large scale
studies (Sarah Field, John Todd, SW and JALA, manuscript in
preparation), but is also in its present form compromised by
interference from a 5’-truncated CCL3L1 pseudogene [10]. The
pseudogene lacks exon 1 and the majority of intron 1, and by
designing our PRT systemwithin intron 1 we have avoided additional
ampliﬁcation from the pseudogene. We have designed a junction-
fragment assay for the presence of the pseudogene (see “Materials and
methods”) which, although not permitting quantiﬁcation of pseudo-
gene copies, has shown that approximately 25% of the UK population
carry at least one copy. Furthermore, presence of the pseudogene is
strongly associated (Pb10−10) with higher copy number — although
about 10% of individuals with 1 or 2 copies of CCL3L1 possess the
pseudogene sequence, it is present more than 80% of individuals with
3 or 4 copies. Assays including the pseudogene sequence in
quantiﬁcation will thus overestimate the copy number of CCL3L1 in
about a quarter of European samples, but will systematically inﬂate
the apparent copy number in most samples with copy numbers above
2. This pseudogene may therefore account in part for the observed
differences in apparent copy number between CCL3L1 and CCL4L1
found in some studies [11,13], especially at higher copy numbers, but
cannot possibly account for the approximately 10% of European
samples reported as having lower copy numbers of CCL3L1 than
CCL4L1, which we therefore assume to reﬂect measurement error. Our
approach also avoids the potential errors affecting array-based
experiments, which also cannot easily differentiate between CCL3L1
and pseudogene copies.
The multiplex assay we describe produces accurate and repro-
ducible data but is dependent on the constant copy number of the
reference loci and the absence of mismatches at primer sites. Failure
to amplify a variant sequence from either test or reference locus or
variation in copy number at reference loci would result in a single-
system discordancy of predictable magnitude on comparison
between the three assays combined in this multiplex. A mismatch
within a primer sequence at the test locus or additional copies of the
reference locus would result in a reduced copy number value in the
affected system, but would not affect the other two assays.
Conversely, failure to amplify two copies of the reference locus due
to either a primer mismatch or a copy number variant would
increase the apparent copy number for the test region. Importantly,
the LTR61 assay uses an unlinked reference locus at which any
sequence or copy number variants would be independent of
variation at the CCL3L1/CCL4L1 locus. The high level of agreement
observed between systems in this study (Fig. 3) indicates that both
single base mismatches and CCL3/CCL4 copy number variants are
rare in European samples.Multiplex PRT produces accurate and reproducible data in the copy
number range common in Europe, but further development is
necessary for a robust typing system for samples of African origin, in
which copy numbers of CCL3L1 appear to range as high as 14 [7].
Preliminary work suggests that adaptation for non-European samples
may not be straightforward. Additional measurement error at all three
systems, in particular unexpected complexity at CCL3A, appears not
merely to be a consequence of measurement of higher copy numbers,
and cannot be explained simply by either mismatches at primer sites
or copy number variants at reference loci. This implicates a complex
pattern of variation which we are continuing to investigate that is
common in African but rare within European populations.
The data we present shows the accurate measurement of the
CCL3L1 locus on chromosome 17, but with careful assay design, a
similar method could be employed in simplifying the accurate
measurement of copy number at many other multiallelic loci, such
as DEFB4 [5,6] and FCGR3B [14]. As a scheme requiring only two PCRs
and a single capillary per sample, themultiplex PRTwe introduce here
is a relatively inexpensive test that can be carried out simply in
microtitre plate format to produce accurate and reproducible data,
and although further clariﬁcation is required before use in typing
samples of African origin, our results show that it is sufﬁciently
accurate to be suitable for use in large scale case–control association
studies in European populations.
Materials and methods
DNA samples
In each experiment DNA samples were used at a concentration of
10 ng/μl. The samples tested were all of European origin, with no
known clinical phenotype. The samples tested were 192 random UK
control DNAs from the European Collection of Cell Cultures (HRC plate
1 and HRC plate 2), 148 randomly selected individuals from
Nottinghamshire and 40 HapMap CEPH (CEU) individuals.
PRT
For each sample, two duplex PCRs were carried out using 5 ng
genomic DNA and 0.5 U Taq DNA polymerase (NEB) in a buffer with
ﬁnal concentrations of 50 mM Tris–HCl pH8.8, 12.5 mM ammonium
sulphate, 1.4 mM magnesium chloride, 7.5 mM 2-mercaptoethanol,
125 μg/ml BSA and 200 μM each dNTP. In one PCR, products were
ampliﬁed with 1 μM each of primers HEX-labelled CCL3AF (TCA-
TAGTGGGTTCTCTGTTTC) with CCL3AR (ATCCAGGGCTGCTTACTT), and
HEX-labelled LTR61AF (AGTTTTCCTCTGCCTAGC) with LTR61AR (TATT-
TATTTTAAGGTGTGCAC), for 24 cycles of 95 °C for 30 s, 55 °C for 30 s,
70 °C for 1 min followed by a ﬁnal hold at 70 °C for 40 min to ensure
complete addition of non-templated A by Taq polymerase. In the
second PCR, products were ampliﬁed using 0.5 μM primers FAM-
labelled CCL4AF (GAGTCTGCTTCCAGTGCT) and CCL4AR (GAG-
GAGTCCTGAGTATGGAG), and 1 μM primers FAM-labelled LTR61AF
and LTR61AR, for 23 cycles of 95 °C for 30 s, 55 °C for 30 s, 70 °C for
1 min followed by a ﬁnal hold at 70 °C for 40 min.
Fragment analysis was carried out by electrophoresis on an
ABI3100 36 cm capillary using POP-4 polymer with an injection
time of 60 s. Products from the two reactions were mixed with 10 μl
HiDi formamide with ROX-500 marker (Applied Biosystems). For the
ECACC and CEPH DNA samples 1 μl of each PCR product was added to
the formamide and for the Nottinghamshire DNAs 1 μl of the HEX
product and 2 μl of FAM product were required for sufﬁcient signal.
Genescan and Genotyper software (Applied Biosystems) were used
to extract the peak areas corresponding to the test and reference peaks
for each of the three systems, and the ratio of test/reference signals
calculated for each sample. Although the use of a single primer pair
minimises the difference in ampliﬁcation efﬁciency of the two
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ampliﬁcation between experiments. To overcome this, copy number
values were calculated by calibrating each experiment assuming that
clustered values correspond with integer copy numbers and applying
a linear regression. In some samples with no copies, this resulted in a
negative copy number, which we rounded to zero. In all but one
sample, the four calibrated values were either in unanimous
agreement on integer copy number, or a single measurement differed
by less than 0.75 from the consensus. (The single DNA sample which
had given repeatedly inconsistent results returned data of greatly
improved quality and consistency after repuriﬁcation of the DNA
(Supplementary Data online); we therefore attribute the poor results
in the ﬁrst round of testing to the low quality of the DNA preparation).
Therefore, for each sample, a simple arithmetic mean of the four copy
number values was calculated. Alternatively, the differences in
observed accuracy between systems could have been used to calculate
a weighted average such that each systemwas scaled according to the
reciprocal of its variance.
Microsatellite analysis
For each microsatellite, PCR was carried out using 5 ng genomic
DNA, 1 μM each primer and 0.5 U Taq DNA polymerase (NEB) in the
same buffer system as for PRT. For TATC17, ampliﬁcation was with
primers TATC17F3 (CTTAGGGGGTCCTCTTGTC) and HEX-labelled
TATC17R (CCAAAATCTGGATTAGTCAG) for 25 cycles of 95 °C for
1 min, 59 °C for 1 min and 70 °C for 1 min, followed by a ﬁnal
extension at 70 °C for 40 min. For TTAT17, ampliﬁcation was with
primers FAM-labelled TTAT17F2 (TCAGTTTTGCAAACGACCA) and
TTAT17R (GAAACTGGAAGGTGGAGATG) for 24 cycles of 95 °C for
30 s, 58 °C for 30 s and 64 °C for 1 min, followed by a 40 min hold step
at 70 °C.
1 μl of each PCR reaction was added to 10 μl HiDi formamide with
ROX-500 marker (Applied Biosystems) and analysed by capillary
electrophoresis on an ABI3100 36 cm capillary with POP-4 polymer
and 60 s injection time. The peak areas for TATC17 and peak heights
for TTAT17 were extracted using Genescan and Genotyper software
(Applied Biosystems) and the ratios between peaks values calculated.
Pseudogene assay
PCR was carried out using three primers in a single reaction — a
forward primer CCL3F near the pseudogene duplication breakpoint
and the reverse primers CCL3R and CCL3PR from the adjacent gene
and pseudogene sequences respectively. Ampliﬁcation with primers
CCL3F (TGGCTGCTCGTCTCAAAGTA) and CCL3R (AATTCCCTGAAGA-
GAACTGAGA) produced a 358 bp control product from CCL3L1.
Ampliﬁcation with CCL3F and an alternative reverse primer, CCL3PR(GTGTGCAAGGACAATGCAAG), produced a 233 bp product speciﬁcally
from the pseudogene. PCR was carried out from 10 ng genomic DNA
with 1 μM primers CCL3F and CCL3PR and 0.5 μM CCL3R and 0.05 U/μl
Taq DNA polymerase (NEB) in the same buffer system as for PRT and
microsatellite ampliﬁcation. The reaction conditions were 95 °C for
5 min, followed by 37 cycles of 95 °C for 1 min, 60 °C for 1 min and
70 °C for 1 min and products were resolved by agarose gel
electrophoresis.
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